secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070336
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q1 net loss $31M; cash $411M; IND cleared for ERAS-0015; cash runway to H2 2028
--------------------------------------------------------------------------------

- Net loss was $31.0M ($0.11/sh) vs $35.0M ($0.23/sh) in Q1 2024; R&D spend decreased to $26.0M from $28.6M.
- Cash, equivalents & marketable securities $411.1M at March 31, 2025; cash runway extended to H2 2028.
- IND cleared for pan-RAS molecular glue ERAS-0015; IND submitted for pan-KRAS inhibitor ERAS-4001.
- Initial Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026.
- Pursuing partnership opportunities for naporafenib to focus on RAS-targeting franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/0000950170-25-070336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/eras-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer